The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
Who is this study for? Adult patients with Asbestosis
What treatments are being studied? Nintedanib
Status: Unknown
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Prospective clinical pilot study for subjects diagnosed with Occupational Progressive Pneumoconiosis. Subjects will be treated with Nintedanib 150mg twice daily for 3 years.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Pneumoconiosis diagnosis confirmed at the Occupational MDT (Occ-MDT)
• diffuse fibrosing lung disease of extent \>10% on HRCT with protocol criteria for progression
• Asbestosis, silicosis, coal worker's pneumoconiosis and diffuse dust fibrosis
• FVC ≥45% predicted and TLCO above 30% predicted
Locations
Other Locations
Australia
Holdsworth House Medical Practice
RECRUITING
Sydney
Contact Information
Primary
Trina Vincent, RN
trina.vincent@holdsworthhouse.com.au
0280381044
Backup
Deborah Yates, A/Prof
deborah.yates@holdsworthhouse.com.au
02 93317228
Time Frame
Start Date: 2020-10-09
Completion Date: 2025-02
Participants
Target number of participants: 100
Treatments
Other: Treatment Arm
Nintedanib 150mg twice daily for 3 years
Related Therapeutic Areas
Sponsors
Collaborators: Boehringer Ingelheim
Leads: Holdsworth House Medical Practice